DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20173762

Buprenorphine/naloxone maintenance therapy in patients with meperidine use disorder

Ahmet Bulent Yazici, Alime Burcin Saykan, Esra Yazici, Atila Erol

Abstract


Meperidine hydrochloride is a synthetic opioid and a weak µ receptor agonist. Meperidine use disorder is mostly iatrogenic and is common in health care workers. In addition, it is prescribed in acute and chronic pain complaints, and has a high potential for creating addiction. Treatment of meperidine use disorder is a challenging issue and there is no standardised treatment for meperidine addiction. Buprenorphine is a μ receptor partial agonist, a long-acting synthetic opioid for the treatment of opioid dependence and has a buprenorphine/naloxone (BN) form combined with naloxone. Buprenorphine maintenance therapy is one of the treatment options performed in opiate use disorder. But there is a paucity of data about treatment of meperidine use disorder. Here, a full remission case report is presented with BN maintenance treatment for a patient with meperidine use disorder diagnosis.


Keywords


Addiction, Buprenorphine, Meperidine, Naloxone, Remission

Full Text:

PDF

References


Evren EC, Ögel K, Çakmak D. Comperison the properties of inpatient meperidine (pethidine) and cannabis abusers. Anatolian Journal of Psychiatry. 2002;3(1):20-7.

Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain physician. 2008;11:133-53.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Arlington, VA: American Psychiatric Association; 2013:541-549.

Unsalan N, Kalyoncu A, Pektas Ö, Mirsal H, Beyazyurek M. Characteristics of inpatient physicians diagnosed with substance use disorders (alcohol and other substances) Anatolian Journal of Psychiatry. 2004;5:148-53.

Geller AK, O'Connor MK. The sickle cell crisis: a dilemma in pain relief. Mayo Clinic proceedings. 2008;83:320-3.

Hung CI, Liu CY, Chen CY, Yang CH, Yeh EK. Meperidine addiction or treatment frustration? General hospital psychiatry. 2001;23:31-5.

Schuckit MA. Treatment of Opioid-Use Disorders. The New England journal of medicine. 2016;375:357-68.

Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). Journal of psychoactive drugs. 2003;35:253-9.

Altintoprak EA, Evren C, Aydemir Ö, Eslek YA, Can Y, Mutlu E, et al. (Clinical Opiate Withdrawal Scale-Cows) Türkçe Sürümünün Güvenilirliği Ve Geçerliliği [Reliability and Validity Study of The Turkish Version of The Clinical Opiate Clinical Scale]. Noro Psikiyatr Ars. 2015;52:89-94.

Flannery BA, Volpicelli JR, Pettinati HM. Psychometric properties of the Penn Alcohol Craving Scale. Alcoholism, clinical and experimental research. 1999;23:1289-95.

Evren C, Gurol DT, Ogel K, Karadag F. Reliability and validity of the Penn Alcohol Craving Scale (PACS) Revised Version for substance craving in male substance dependent inpatients. Turk Psikiyatri Derg. 2011;22:70.

Ozer U, Sever A, Cetin T, Evren C. Meperidin bağımlılığı ve kronik ağrı birlikteliğinde venlafaksin tedavisi: Bir olgu sunumu [Venlafaxine pharmacotherapy in meperidine addiction and chronic pain comorbidity: a case report]. Dusunen Adam. 2010;23:69-72.

Annagür BB. A Nurse with Pethidine Addiction. European Journal of General Medicine. 2012;9:59-61.

Reifenschweiler DOH, Schoof-Beelen T, Schellekens SDeA. Treatment for iatrogenic opioid dependence: good results with buprenorphine/naloxon. Ned Tijdschr Geneeskd. 2013;157:154.

Davids E, Gastpar M. Buprenorphine in the treatment of opioid dependence. European neuropsycho pharmacology: the journal of the European College of Neuropsycho pharmacology. 2004;14:209-16.

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane database of systematic reviews. 2014:CD002207.

Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, Hans G, et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain practice: The official journal of World Institute of Pain. 2008;8:287-313.

Strain EC, Lofwall MR, Jaffe JH. Opioid related disorders In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry 9th; Lippincott Williams & Wilkins; 2009:1382.